No Data
No Data
ATyr Pharma Stockholders Endorse Leadership and Progress
ATyr Pharma Buy Rating: Novel Treatment's Market Potential and Financial Upside
Express News | ATyr Pharma Inc : Jonestrading Assumes Coverage With Buy Rating; Target Price $22
Express News | ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Analysts' Top Healthcare Picks: ATyr Pharma (LIFE), Dynavax (DVAX)
Express News | ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications